IDIA Share Price Performance
CHF 3.08
2.01 (188.93%)
36.3% undervalued intrinsic discount
CHF 4.83
Fair Value
Price CHF 3.08
AnalystConsensusTarget CHF 4.83
AnalystHighTarget CHF 6.00
AnalystLowTarget CHF 4.00
Fair ValueCHF 4.50
Share Pricen/a
Idorsia Ltd Stock Price
- 3 Narratives written by author
- 1 Comments on narratives written by author
- 11 Fair Values set on narratives written by author
IDIA Community Narratives
AN
Fair Value CHF 4.5 31.6% undervalued intrinsic discount
IDIA: Near-Term Risks Will Likely Limit Upside Despite Price Target Lift
0users have liked this narrative
1users have commented on this narrative
8users have followed this narrative
AN
Fair Value CHF 6 48.7% undervalued intrinsic discount
Global Insomnia Franchise And Hypertension Breakthrough Will Drive Long Term Earnings Power
1users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value CHF 4 23.0% undervalued intrinsic discount
Insomnia And Hypertension Therapies Will Support Stable Prospects Despite Pipeline And Partnering Risks
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
IDIA: Near-Term Risks Will Likely Limit Upside Despite Price Target Lift
Key Takeaways Market optimism for rapid revenue growth may be premature, with unvalidated access, uncertain drug uptake, and regulatory outcomes adding risk to earnings expectations. Longer-term valuation appears inflated by pipeline commercialization hopes, while rising costs and increasing pricing scrutiny threaten future margins and profitability.Read more
236
users have viewed this narrative0users have liked this narrative
1users have commented on this narrative
8users have followed this narrative
AN
CHF 4.5
31.6% undervalued intrinsic discount
Fair Value
Profit Margin
12.88%
Future PE
33.04x
Price in 2029
CHF 5.49
Insomnia And Hypertension Therapies Will Support Stable Prospects Despite Pipeline And Partnering Risks
Catalysts About Idorsia Idorsia is a science driven biopharmaceutical company that develops and commercializes innovative therapies in insomnia, resistant hypertension, rare diseases, and immunology. What are the underlying business or industry changes driving this perspective?Read more
24
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
CHF 4
23.0% undervalued intrinsic discount
Fair Value
Profit Margin
20.01%
Future PE
16.79x
Price in 2028
CHF 4.75
Global Insomnia Franchise And Hypertension Breakthrough Will Drive Long Term Earnings Power
Catalysts About Idorsia Idorsia is a science driven biopharmaceutical company developing and commercializing innovative therapies targeting major unmet medical needs in cardiovascular disease, insomnia, rare disorders, and infectious disease. What are the underlying business or industry changes driving this perspective?Read more
33
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
CHF 6
48.7% undervalued intrinsic discount
Fair Value
Profit Margin
20.01%
Future PE
25.49x
Price in 2028
CHF 7.16
Trending Discussion
Recently Updated Narratives
AN
IDIA: Fabry And Resistant Hypertension Progress Will Continue To Drive Future Upside
Fair Value: CHF 4.5 31.6% undervalued intrinsic discount
8 followersusers have followed this narrative
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
Insomnia And Hypertension Therapies Will Support Stable Prospects Despite Pipeline And Partnering Risks
Fair Value: CHF 4 23.0% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Global Insomnia Franchise And Hypertension Breakthrough Will Drive Long Term Earnings Power
Fair Value: CHF 6 48.7% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Idorsia Ltd Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Apr 28, 2026
- -0.44
- 44.18%
- -50.64%
- -101.6%
About IDIA
- Founded
- 2017
- Employees
- n/a
- CEO
- WebsiteView website
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company’s product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat fabry disease; Daridorexant, a dual orexin receptor antagonist, which is in phase 2 clinical trial for the treatment of pediatric insomnia; IDOR-1117-2520, a CCR6 receptor antagonist which is in phase 1 clinical program to treat psoriasis; ACT-777991, a CXCR3 antagonist, which is in preclinical trial to treat vitiligo; and ACT-1004-1239, an ACKR3 receptor antagonist which is preclinical trial for the treatment of progressive multiple sclerosis. It also develops ACT-1016-0707, a LPA 1 receptor antagonist to treat immune-mediated and fibrosis related disorders; IDOR-1141-8472, an orexin 2 receptor agonist to treat orexin-related CNS disorders; and IDOR-1126-6421 to treat organ injury. The company holds a license agreement with Neuro to develop and commercialize clazosentan; collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; and collaboration with Viatris Inc. to develop and commercialize selatogrel and cenerimod. Idorsia Ltd was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
